Overexpression of GNAO1 correlates with poor prognosis in patients with gastric cancer and plays a role in gastric cancer cell proliferation and apoptosis

International Journal of Molecular Medicine

Volumn 33, Issue 3, 2014, Pages 589-596

  Liu, Zhen ^a   Zhang, Jun ^b   Wu, Lijun ^b   Liu, Jie ^b   Zhang, Mingqing ^a  

^a XIAMEN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Alpha activating activity polypeptide O; Apoptosis; Gastric cancer; Guanine nucleotide binding protein (G protein); Proliferation

Indexed keywords

AGED; AGED, 80 AND OVER; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; PROGNOSIS; STOMACH NEOPLASMS;

EID: 84893872771     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1598     Document Type: Article

References (27)

1. Nakamura T, Nakatsu N, Yoshida Y, et al: Identification of candidate genes determining chemosensitivity to anti-cancer drugs of gastric cancer cell lines. Biol Pharm Bull 32: 1936-1939, 2009.
2. Ji YB, Qu ZY and Zou X: Juglone-induced apoptosis in human gastric cancer SGC-7901 cells via the mitochondrial pathway. Exp Toxicol Pathol 63: 69-78, 2011.
3. Jackson C, Cunningham D and Oliveira J: Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20 Suppl 4: 34-36, 2009.
4. Wang WF, Li J, Du LT, et al: Krüppel-like factor 8 overexpression is correlated with angiogenesis and poor prognosis in gastric cancer. World J Gastroenterol 19: 4309-4315, 2013.
5. Yamada Y, Boku N, Nishina T, et al: Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: Correlative study in Japan Clinical Oncology Group Trial JCOG9912. Ann Oncol 24: 2560-2565, 2013.
6. Li X, Qi W, Yao R, Tang D and Liang J: Overexpressed transcription factor FOXM1 is a potential diagnostic and adverse prognostic factor in postoperational gastric cancer patients. Clin Transl Oncol: Jul 20, 2013 (Epub ahead of print).
7. Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150, 2006.
8. Neer EJ, Lok JM and Wolf LG: Purification and properties of the inhibitory guanine nucleotide regulatory unit of brain adenylate cyclase. J Biol Chem 259: 14222-14229, 1984.
9. Gierschik P, Milligan G, Pines M, et al: Use of specific antibodies to quantitate the guanine nucleotide-binding protein Go in brain. Proc Natl Acad Sci U S A 83: 2258-2262, 1986.
10. Corre I, Baumann H and Hermouet S: Regulation by Gi2 proteins of v-fms-induced proliferation and transformation via Src-kinase and STAT3. Oncogene 18: 6335-6342, 1999.
11. Fan X, Brass LF, Poncz M, Spitz F, Maire P and Manning DR: The alpha subunits of Gz and Gi interact with the eyes absent transcription cofactor Eya2, preventing its interaction with the six class of homeodomain-containing proteins. J Biol Chem 275: 32129-32134, 2000.
12. Montminy M: Transcriptional regulation by cyclic AMP. Annu Rev Biochem 66: 807-822, 1997.
13. Kan Z, Jaiswal BS, Stinson J, et al: Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466: 869-873, 2010.
14. Jia D, Wei L, Guo W, et al: Genome-wide copy number analyses identified novel cancer genes in hepatocellular carcinoma. Hepatology 54: 1227-1236, 2011.
15. Garcia-Marcos M, Ghosh P and Farquhar MG: Molecular basis of a novel oncogenic mutation in GNAO1. Oncogene 30: 2691-2696, 2011.
16. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
17. Wang XN and Liang H: Some problems in the surgical treatment of gastric cancer. Chin J Cancer 29: 369-373, 2010.
18. Nguyen DX, Bos PD and Massagué J: Metastasis: From dissemination to organ-specific colonization. Nat Rev Cancer 9: 274-284, 2009.
19. Freeman A, Morris LS, Mills AD, et al: Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res 5: 2121-2132, 1999.
20. Tait SW and Green DR: Mitochondria and cell death: Outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 11: 621-632, 2010.
21. Bratton MR, Antoon JW, Duong BN, et al: Gao potentiates estrogen receptor a activity via the ERK signaling pathway. J Endocrinol 214: 45-54, 2012.
22. Baines CP and Molkentin JD: STRESS signaling pathways that modulate cardiac myocyte apoptosis. J Mol Cell Cardiol 38: 47-62, 2005.
23. Fan Y, Chen H, Qiao B, et al: Opposing effects of ERK and p38 MAP kinases on HeLa cell apoptosis induced by dipyri-thione. Mol Cells 23: 30-38, 2007.
24. Raman M, Chen W and Cobb MH: Differential regulation and properties of MAPKs. Oncogene 26: 3100-3112, 2007.
25. Youle RJ and Strasser A: The BCL-2 protein family: Opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59, 2008.
26. Balmanno K and Cook SJ: Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ 16: 368-377, 2009.
27. Bean GR, Ganesan YT, Dong Y, et al: PUMA and BIM are required for oncogene inactivation-induced apoptosis. Sci Signal 6: Ra20, 2013.